Skip to main content
Fig. 2 | Journal of Hematology & Oncology

Fig. 2

From: Prognostic and therapeutic value of disruptor of telomeric silencing-1-like (DOT1L) expression in patients with ovarian cancer

Fig. 2

Knocking down of DOT1L inhibits the proliferation of ovarian cancer cells. a Western blot analysis of DOT1L expression in various ovarian cancer cell lines. GAPDH was used as loading control. b RT-PCR analysis of endogenous DOT1L mRNA expression in SK-OV-3 and TOV21G cells that were transfected with shRNAs lentiviral articles against DOT1L as indicated in the figure. The shRNAs were able to knockdown DOT1L. c Western blot analysis of SK-OV-3 and TOV21G cells transfected with shDOT1L shRNAs. The blot was probed with DOT1L and H3K79me2 antibodies. GAPDH and H3 were used as loading control. d The cell proliferation of SK-OV-3 and TOV21G was determined by CCK-8 assay after shDOT1L shRNAs transfection (n = 3). The results are representative of three independent experiments. P < 0.05. e The colony formation assay was performed in SK-OV-3 and TOV21G cells after shDOT1L shRNAs transfection (n = 3). Representative images (left) and the histogram (right) of three independent experiments were shown. P < 0.05. f SK-OV-3 and TOV21G cells were seeded in 96-well plates and cultured in the presence of SGC0946 at variable concentrations (0, 0.2, 2, or 20 μM) for up to 12 days. Then, the OD450 values of corresponding cells were measured at 0, 3, 6, 9, and 12 days after SGC0946 treatment. The results are representative of three independent experiments. (n = 3, P < 0.05). g The colony formation assay was performed in SK-OV-3 and TOV21G cells after 10 μM EPZ004777 and 10 μM SGC0946 treatment for up to 12 days. Representative images (left) and the histogram (right) of three independent experiments were shown. (n = 3, P < 0.05)

Back to article page